Sermorelin 5mg — Native GHRH 1-29 HPLC ≥98% Purity

Zoom

31,00 €

Tax included • Free delivery from 99€

+1,55 € in loyalty cashback, with an account. Create my account

Only 4 left, flying off the shelf!

Next dispatch: Saturday, October 3

In stock in France

Subscription

27,90 €-10 %instead of 31,00 €

-10 % for life on each cyclePause, skip or cancel in 1 clickNo commitment, no hidden fees

Your complete kit

5mg vialIncluded
Bacteriostatic waterAdd
1 ml syringesAdd

The vial alone cannot be used as is. One sealed vial of Sermorelin 5mg, lyophilised, without individual labelling.

Don't forget the essentials

Eau Bactériostatique

7,90 €

Seringue de précision 1ml 29Gx107,90 €

Lingettes alcool isopropylique 70%x103,90 €

Our Sermorelin 5 mg vial is the historical reference of the GHRH analog class for somatotropic axis research. Initially developed in the 1980s under the name Geref by Serono, Sermorelin corresponds to the 1-29 fragment of human GHRH (truncated native sequence, amino acids 1 to 29 of 44), considered the minimal active site for GHRH-R receptor binding. With 5 mg of lyophilized peptide per vial at HPLC purity ≥98 %, this format covers approximately 15-25 days of protocol at the typical 200-500 mcg/day dose. Sermorelin presents a short pharmacokinetic profile (10-15 minute half-life) requiring daily administrations, unlike CJC-1295 DAC (6-8 day half-life). This rapid kinetics allows quick return to baseline and mimics endogenous pulsatile physiology. Sermorelin remains the historical reference for research protocols seeking to avoid chronic GHRH-R axis stimulation.

Science

01
Mechanism of action

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the first 29 N-terminal residues of native human GHRH (the complete molecule has 44 amino acids). Molecular weight 3358 Da. Truncation at position 29 fully preserves the active site necessary for GHRH-R receptor activation, while simplifying chemical synthesis and offering sufficient stability for clinical use.

At the molecular level, Sermorelin activates the GHRH-R receptor expressed on the surface of somatotropic cells of the anterior pituitary. Receptor binding triggers a Gs-cAMP-PKA signaling cascade leading to GH synthesis and its pulsatile release from storage granules. Sermorelin faithfully reproduces the action of endogenous native GHRH, preserving the physiological pulsatility of GH secretion — a critical element since pulses are essential to downstream tissue response (IGF-1, lipolysis, protein synthesis).

Pharmacokinetically, Sermorelin presents a short plasma half-life of 10-15 minutes after subcutaneous administration. The GH plasma peak is observed at 30-60 minutes, with return to baseline values in 2-3 hours. This rapid kinetics mimics endogenous physiology: native GHRH is itself secreted pulsatilely with a very short plasma half-life.

GHRH-R receptor activation by Sermorelin does NOT produce significant increases in prolactin, cortisol, or ACTH. It depends on physiological pulsatile stimulation rather than continuous exposure, thus avoiding receptor desensitization. Sermorelin thus retains its efficacy over extended protocols, unlike certain GHRH analogs with overly extended kinetics.

Unlike GHRPs (Ipamorelin, GHRP-6) which act via the GHS-R1a receptor (ghrelin receptor), Sermorelin remains strictly in the GHRH-R pathway. A synergy is documented in combination with selective GHRPs (Ipamorelin), although the CJC-1295 DAC + Ipamorelin combination is more studied in recent literature. As with any research peptide, these data come from preclinical and historical clinical studies: Sermorelin was marketed under the name Geref for the treatment of GH deficiency in children between 1997 and 2008, then withdrawn from the American market for commercial reasons.

Clinical data

02Clinical studies

The scientific corpus on Sermorelin is one of the oldest and most documented in the GHRH analog class, with over three decades of publications covering pharmacokinetics, pharmacodynamics, pediatric and geriatric clinical trials.

Thorner et al. (Journal of Clinical Endocrinology & Metabolism 1986; DOI 10.1210/jcem-62-5-1046) published one of the first foundational studies on Sermorelin (then designated "hpGHRH 1-29-NH2"), documenting in healthy adults dose-dependent GH stimulation after subcutaneous administration. This work laid the foundation for subsequent clinical development.

Gelato et al. (JCEM 1983, 1984) had previously studied the pharmacology of native 1-44 GHRH in humans, providing the comparative framework that validated Sermorelin 1-29 as functional equivalent. The absence of clinically significant difference between the two forms justified the choice of the truncated fragment for commercial development (more economical to synthesize).

Vittone et al. (JCEM 1997; DOI 10.1210/jcem.82.12.4451) conducted a landmark study in healthy older subjects, documenting partial restoration of GH pulses and IGF-1 increase after daily Sermorelin for 16 weeks. This study inspired numerous research protocols on somatotropic aging.

Corpas et al. (JCEM 1993) studied the pituitary response to Sermorelin in normal older subjects, documenting a preserved but attenuated response compared to young subjects — suggesting a progressive decline in pituitary sensitivity with age.

On the pediatric front, Sermorelin was FDA-approved in 1997 under the name Geref for the diagnosis and treatment of GH deficiency in children. Several controlled clinical trials in children with idiopathic short stature documented an increase in growth velocity over 6-12 months. Sermorelin was withdrawn from the American market in 2008 for commercial reasons (abandonment by Serono/EMD Merck).

More recently, American private clinics have explored compassionate Sermorelin use in compounding pharmacies in adults wishing to optimize their somatotropic axis (off-label). None of these uses are approved by the FDA or EMA.

Corpus limitations: despite its age, Sermorelin has been supplanted in modern research by extended half-life GHRH analogs (CJC-1295 DAC, Tesamorelin). Long-term data (>2 years) are limited in adults. Sermorelin remains strictly a research peptide outside historical pediatric indications.

1
Déficit GH adulteSermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Walker RF · Clinical Interventions in Aging · 2006
2
Diagnostic GHDSermorelin: a review of its use in the diagnosis and treatment of children with idiopathic or neurogenic growth hormone deficiency
Prakash A, Goa KL · BioDrugs · 1999

The listed studies are provided for documentation and research purposes only. They do not constitute a therapeutic indication nor a recommendation for human use. This product is strictly for laboratory use only (RUO).

Lab workflow

03
Research protocols

Recommended reconstitution: 2 ml bacteriostatic water for injection → final concentration 2.5 mg/ml. Alternative volume: 1 ml (5 mg/ml, for high doses). Procedure: 1) let vial and diluent reach room temperature (15 minutes); 2) disinfect stopper with 70% alcohol; 3) draw bacteriostatic water into sterile syringe; 4) inject slowly along inner wall of vial; 5) gently swirl until dissolution — no vigorous shaking. Dosages reported in literature: historical clinical studies (pediatric and geriatric) used 30 mcg/kg in daily subcutaneous administration. Exploratory human research protocols (outside authorized therapeutic framework) typically mention 200 to 500 mcg per injection, 1 to 2 times daily subcutaneously. The documented optimal timing is at bedtime to maximize synergy with physiological GH pulses of deep sleep (N3 stage). At 2.5 mg/ml concentration, 200 mcg corresponds to 0.08 ml (8 units on 100 IU syringe), 300 mcg to 0.12 ml (12 units), 500 mcg to 0.2 ml (20 units). Autonomy: 5 mg allows approximately 25 days at 200 mcg/day, 17 days at 300 mcg/day, or 10 days at 500 mcg/day. Ideal pilot format for a 2-4 week exploratory cycle. Documented synergy: although less studied in modern research, Sermorelin can be combined with a selective GHRP (Ipamorelin, 200-300 mcg) to exploit the GHRH-R + GHS-R1a synergy. However, most current secretagogue protocols favor CJC-1295 DAC (extended half-life) + Ipamorelin. Physiological timing: bedtime injection is preferred to synchronize the Sermorelin effect with the nocturnal physiological GH peak during deep slow-wave sleep. Avoid post-meal injection rich in carbohydrates or lipids that attenuate GH response. Post-reconstitution storage: refrigerator 2-8 degrees Celsius, 14-21 day usage window with bacteriostatic (shorter reconstitution half-life than modern stabilized peptides).

Reconstitution for this format (5 mg)Standard volumes used in laboratory settings

Water added	Concentration	Reading marker
1 ml	5 mg/ml	40 UI = 2 mg
2 ml	2,5 mg/ml	40 UI = 1 mg

The volume of water does not change the product, only its concentration. Introduce the water slowly along the vial wall, never directly onto the lyophilisate, then swirl without shaking. Markers given on a 1 ml syringe graduated in 100 units.

Asepsis

Disinfect surfaces and stoppers (70% alcohol).

Solvent

Draw the required volume of bacteriostatic water.

Introduction

Inject gently against the vial wall (avoid direct jet on powder).

Solubilization

Roll the vial gently. Do not shake vigorously (degradation risk).

Solution storageOnce reconstituted: 2-8°C (refrigerator).

WarningTheoretical tool for chemical handling. Does not constitute medical advice.

I open the dilution calculator

What is normal on arrivalThe observations that worry customers, and are not defects

The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
The vial carries no individual label. That is our standard packaging, not a downgraded vial.
After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
The parcel is plain. Nothing on the outside indicates the contents or the brand name.

What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.

Handling

04Storage & handling

Lyophilized unreconstituted Sermorelin can be stored for up to 24 months at -20 degrees Celsius in its original sealed packaging, protected from light and humidity. At refrigerated temperature (2-8 degrees Celsius), documented stability covers a minimum of 12 months. At room temperature (below 25 degrees Celsius), recommended duration for transport or temporary storage: 2 weeks maximum (Sermorelin is more sensitive than modern extended half-life peptides). Once reconstituted with bacteriostatic water, Sermorelin must be stored between 2 and 8 degrees Celsius. Documented post-reconstitution stability: 14-21 days with bacteriostatic (benzyl alcohol 0.9%), 5-7 days with preservative-free sterile water. This relatively short stability compared to modern peptides reflects the native (unmodified) nature of the 1-29 sequence. Specific sensitivities: Sermorelin is particularly sensitive to degradation by dipeptidyl peptidase IV (DPP-IV) in biological environment — hence its short 10-15 minute plasma half-life. In vitro, avoid repeated freeze-thaw cycles (limit to three), UV exposure, thermal shocks, and contact with non-inert metallic surfaces. Prefer aliquots for large-volume formats.

01Why choose Sermorelin over CJC-1295 DAC?

Sermorelin offers more physiological kinetics (10-15 minute half-life vs 6-8 days for CJC-1295 DAC), enabling intermittent pulsatile stimulation cycles without chronic GHRH-R receptor sensitization. It suits protocols seeking to preserve natural somatotropic axis reactivity and avoid plateaus linked to prolonged exposure. CJC-1295 DAC remains preferred to maximize duration of action and reduce injection frequency (1/week vs 1-2/day for Sermorelin).

02How do I reconstitute Sermorelin 5 mg?

Inject 2 ml bacteriostatic water into the vial: 5 mg / 2 ml = 2.5 mg/ml. Typical 200-300 mcg dose corresponds to 8-12 units on 100 IU syringe. Procedure: diluent along the inner wall (never onto lyophilisate), gentle rotation until complete dissolution, no shaking. Post-reconstitution storage: 2-8 degrees Celsius, 14-21 day window with bacteriostatic (shorter than modern extended half-life peptides).

03When to inject Sermorelin?

The documented optimal timing in literature is at bedtime (between 30 min and 1 h before falling asleep), to synchronize the Sermorelin effect with the nocturnal physiological GH peak during deep slow-wave sleep (N3 stage). A second relevant timing is morning fasted. Avoid injection 2 hours before or after a carbohydrate- or lipid-rich meal that attenuates GH response. Sermorelin can also be used pre-workout to stimulate a pre-exercise GH pulse.

04Can Sermorelin be combined with a GHRP?

Yes, the Sermorelin (GHRH analog, GHRH-R pathway) + Ipamorelin (selective GHRP, GHS-R1a/ghrelin pathway) combination exploits the synergy of the two independent secretagogue pathways, amplifying GH pulsatility. Typical protocol: 200-300 mcg Sermorelin + 200-300 mcg Ipamorelin in simultaneous injection 1-2 times daily. In modern research, the CJC-1295 DAC + Ipamorelin combination is however more studied and offers better logistics (weekly injection instead of daily for the GHRH component).

05Which biological markers to track under Sermorelin?

Protocols typically track: serum GH (post-injection profile over 4 hours), IGF-1 and IGFBP-3 (integrated markers at 1-2 weeks), fasting glycemia and HbA1c, morning cortisol and prolactin (pure GHRH-R pathway control), hepatic and lipid panel, complete blood count. In adults or elderly, a baseline thyroid workup is also recommended pre-protocol. No validated human therapeutic standard exists outside historical pediatric indications.

06Is your Sermorelin authentic?

Sermorelin is synthesized by solid-phase peptide synthesis (SPPS) with HPLC purity ≥98 %. The sequence fully corresponds to the first 29 amino acids of native human GHRH.

07What is the delivery lead time in Europe?

Order today, shipped the next day: dispatch Monday to Saturday from our stock in France, with real-time tracking from dispatch. Allow 2 to 5 business days in France, 3 to 5 to Belgium, Luxembourg, Germany and the Netherlands, 4 to 7 to the rest of the EU. No customs within the EU, free shipping from €99 in France and from €150 in the EU.

08What is the documented tolerance profile?

Sermorelin benefits from the oldest clinical corpus in the GHRH analog class (over 30 years of data). Pediatric and geriatric trials have documented a favorable tolerance profile, with predominantly local injection site reactions (erythema, transient pain) and occasionally transient flush, mild headaches, or strange taste. The absence of prolactin/cortisol/ACTH stimulation distinguishes Sermorelin from non-selective GHRPs. No serious cardiovascular effects reported at therapeutic doses. The historical pediatric Geref profile served as FDA reference for adult tolerance assessment.

Benchmark

Similar peptides

Sermorelin occupies a historical position in the GHRH analog class, being the first to obtain FDA approval (1997, commercial name Geref). Its short kinetic profile faithfully reproduces the endogenous physiology of native GHRH.

Compared to CJC-1295 DAC (tetra-substituted GHRH analog with Drug Affinity Complex, 6-8 day half-life), Sermorelin presents a radically different kinetics (10-15 minute half-life). Sermorelin mimics physiological pulsatility while CJC-1295 DAC maintains chronic GHRH-R receptor sensitization. For protocols seeking to avoid prolonged stimulation, Sermorelin remains relevant. To maximize duration of action and reduce injection frequency, CJC-1295 DAC is preferred.

Compared to CJC-1295 without DAC (Mod GRF 1-29, tetra-substituted but without albumin conjugation, 30-minute half-life), Sermorelin is the unmodified native sequence. Effects are comparable but Mod GRF 1-29 plasma stability is slightly superior thanks to D-Ala2/Gln8/Ala15/Leu27 substitutions protecting against DPP-IV.

Compared to Tesamorelin (GHRH analog marketed under the name Egrifta for HIV lipodystrophy, trans-3-hexenoic acid linked to position 1), Tesamorelin presents an intermediate half-life of 26-38 minutes and retains increased plasma stability. Tesamorelin obtained maintained FDA approval and is produced under strict therapeutic formulation.

Compared to GHRPs (Ipamorelin, GHRP-6, Hexarelin), Sermorelin acts on a completely different pathway: GHRH-R versus GHS-R1a/ghrelin. The two pathways are independent and synergistic. The Sermorelin + Ipamorelin combination is a valid research option although less popular than CJC-1295 DAC + Ipamorelin in modern literature.

Compared to exogenous recombinant GH (somatropin), Sermorelin preserves the physiological pulsatility of endogenous secretion, which maintains better tissue response and avoids GH receptor desensitization according to literature.

On the research peptide market, Sermorelin maintains stable demand for protocols seeking short and physiological kinetics, even though it is supplanted in popularity by CJC-1295 DAC. Its commercialization for human therapeutic use remains limited to American compounding pharmacies outside historical pediatric indications — strict research use in Europe.

Sermorelin 5mg Anti-Aging

Longevity

01
Mechanism of action

02Clinical studies

03
Research protocols

Asepsis

Solvent

Introduction

Solubilization

04Storage & handling

Similar peptides

Longevity

Product information

Asepsis

Solvent

Introduction

Solubilization

Complementary reagents